Abstract
Myeloproliferative neoplasms (MPN)-such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF)-are typically diseases of the elderly caused by acquired somatic mutations. However, it is largely unknown how the malignant clone interferes with normal hematopoiesis. In this study, we analyzed if serum of MPN patients comprises soluble factors that impact on hematopoietic stem and progenitor cells (HPCs). CD34+ HPCs were cultured in medium supplemented with serum samples of PV, ET, or MF patients, or healthy controls. The impact on proliferation, maintenance of immature hematopoietic surface markers, and colony forming unit (CFU) potential was systematically analyzed. In addition, we compared serum of healthy young (<25 years) and elderly donors (>50 years) to determine how normal aging impacts on the hematopoiesis-supportive function of serum. Serum from MF, PV and ET patients significantly increased proliferation as compared to controls. In addition, serum from MF and ET patients attenuated the loss of a primitive immunophenotype during in vitro culture. The CFU counts were significantly higher if HPCs were cultured with serum of MPN patients as compared to controls. Furthermore, serum of healthy young ...Continue Reading
References
May 2, 1994·Journal of Immunological Methods·A B Lyons, C R Parish
Apr 20, 2005·Cancer Cell·Ross L LevineD Gary Gilliland
Aug 24, 2005·British Journal of Haematology·Katerina E PanteliKonstantinos L Bourantas
Dec 8, 2006·The New England Journal of Medicine·Peter J Campbell, Anthony R Green
Mar 3, 2007·Leukemia Research·Ching-Liang HoAyalew Tefferi
Jul 28, 2007·Experimental Hematology·Katharina S GötzeRobert A J Oostendorp
Aug 30, 2008·Stem Cells and Development·Anna Marciniak-CzochraWolfgang Wagner
Aug 30, 2008·Leukemia·R Kralovics
May 13, 2009·Journal of Cellular and Molecular Medicine·Thomas WalendaWolfgang Wagner
Feb 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew TefferiAnimesh Pardanani
Mar 2, 2011·Experimental Hematology·Thomas WalendaWolfgang Wagner
Mar 26, 2011·PloS One·Thomas WalendaWolfgang Wagner
Jul 20, 2011·The Journal of Experimental Medicine·Cornelis J H PronkSten Eirik W Jacobsen
Aug 24, 2011·Blood·Angela G FleischmanMichael W Deininger
Nov 30, 2011·Proceedings of the National Academy of Sciences of the United States of America·Wendy W PangIrving L Weissman
Aug 7, 2012·Leukemia·X LinJ D Licht
Sep 12, 2012·American Journal of Hematology·Rakhee VaidyaAyalew Tefferi
Feb 19, 2013·Cytokine & Growth Factor Reviews·Hans C Hasselbalch
Mar 7, 2013·Blood·Maria ZingarielloAnna Rita Migliaccio
Apr 4, 2013·Blood·Sarah GrasedieckFlorian Kuchenbauer
Apr 16, 2013·Nature Reviews. Immunology·Hartmut GeigerM Carolina Florian
Jul 5, 2013·Blood·Tiziano BarbuiAnna Falanga
Jul 16, 2013·Cell Stem Cell·Koen SchepersEmmanuelle Passegué
Jan 28, 2014·Experimental Hematology·Emmanuel PourcelotPascal Mossuz
Apr 26, 2014·PLoS Computational Biology·Thomas WalendaWolfgang Wagner
Feb 20, 2015·Hematology·Edwin Chen, Ann Mullally
May 27, 2015·The Journal of Clinical Investigation·Lukas F MagerPhilippe Krebs
May 30, 2015·Blood·Min LuRonald Hoffman
May 30, 2015·PloS One·Thomas WalendaWolfgang Wagner
Oct 23, 2015·Mediators of Inflammation·Vladan P ČokićPuri K Raj
Nov 6, 2015·Mediators of Inflammation·Sylvie HermouetBetty Gardie
Feb 9, 2016·Leukemia·S KoschmiederT Barbui
Nov 30, 2016·Frontiers in Immunology·Larisa V KovtonyukHitoshi Takizawa